S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Will This Be the Worst U.S. Crisis Ever? (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Will This Be the Worst U.S. Crisis Ever? (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Will This Be the Worst U.S. Crisis Ever? (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Will This Be the Worst U.S. Crisis Ever? (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Will This Be the Worst U.S. Crisis Ever? (Ad)
CVE:AQS

Aequus Pharmaceuticals - AQS Stock Forecast, Price & News

C$0.06
+0.01 (+8.33%)
(As of 08/11/2022 05:17 PM ET)
Add
Compare
Today's Range
C$0.06
C$0.07
50-Day Range
C$0.05
C$0.08
52-Week Range
C$0.02
C$0.16
Volume
26,000 shs
Average Volume
53,874 shs
Market Capitalization
C$8.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AQS stock logo

About Aequus Pharmaceuticals (CVE:AQS) Stock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Stock News Headlines

IIROC Trading Resumption - AQS
Aequus Resumes Trading on TSX Venture Exchange
IIROC Trading Halt - AQS.WT
IIROC Trading Halt - AQS.DB
Aequus Announces Director Resignation
Aequus Provides Commercial Update
Aequus Provides update on Warrant Acceleration
Aequus Closes $1 Million Financing
Aequus Announces Anne Stevens' Leadership Change
AEQUUS PHARMACEUTICALS (AEQ.MU)
Aequus Pharmaceuticals Inc. Reg (AEQ.SG)
See More Headlines
Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Company Calendar

Last Earnings
6/30/2022
Today
8/13/2022
Next Earnings (Estimated)
8/29/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$2.53 million
Cash Flow
C$0.02 per share
Book Value
C$0.01 per share

Miscellaneous

Free Float
N/A
Market Cap
C$8.62 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Douglas Glen Janzen (Age 53)
    Chairman & CEO
    Comp: $225k
  • Ms. Ann Fehr CGA (Age 53)
    CPA, CFO & Corp. Sec.
    Comp: $155.94k
  • Mr. Stuart Fowler
    Strategic Commercial Advisor & Independent Director
  • Mr. Grant Larsen
    Chief Commercial Officer













AQS Stock - Frequently Asked Questions

How have AQS shares performed in 2022?

Aequus Pharmaceuticals' stock was trading at C$0.12 at the beginning of 2022. Since then, AQS shares have decreased by 43.5% and is now trading at C$0.07.
View the best growth stocks for 2022 here
.

When is Aequus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022.
View our AQS earnings forecast
.

How were Aequus Pharmaceuticals' earnings last quarter?

Aequus Pharmaceuticals Inc. (CVE:AQS) posted its quarterly earnings data on Thursday, June, 30th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.30 million for the quarter.

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle International (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF).

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.07.

How much money does Aequus Pharmaceuticals make?

Aequus Pharmaceuticals (CVE:AQS) has a market capitalization of C$8.62 million and generates C$2.53 million in revenue each year.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The official website for the company is www.aequuspharma.ca. The company can be reached via phone at +1-604-3367906.

This page (CVE:AQS) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.